KARD logo

KARDIGAN INC

KARDNASDAQ
🏆 #2259 by market capUS Equity
$14.67▼ $0.12 (−0.84%)
After hours · at close
🔔
Track KARD
Get earnings, price moves & breaking news on Telegram
Track
24h▼ 0.8%
7d▼ 10.8%
14d▼ 20.8%
30d▼ 26.6%
ytd—
1y—
🏦Market Cap
$1.31B
Small Cap
📈Revenue Growth (YoY)
—
📊Gross Margin
—
💵FCF Margin
—
⚖️P/S Ratio
—
Otter Score
72
Fair

Trading Snapshot

Day Range
$14.49 – $14.94
52-Week Range
$13.75 – $27.00
Volume
$2.24B
Avg Volume
$1.57B
Shares Outstanding
89.3M
Next Earnings
Nov 3, 2026

Fundamentals Snapshot

Annual Revenue
$128M
Last Q Revenue
$30M
P/E Ratio
—
P/S Ratio
—
EPS (TTM)
$-7.39
Dividend Yield
—

Why Investors Own KARD

  • ✓High-growth profile — revenue up +7.8% YoY with expanding US Equity exposure.
  • ✓Healthy economics — 68% gross margin and 8% free-cash-flow margin.
  • ✓New products and segments could unlock additional revenue streams.
⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

KARD logo

KARDIGAN INC

KARD
Financial Trends
Revenue (TTM)The total money the company brought in from sales, before subtracting any costs.
$128M▲ +6.9% YoY
Gross Margin (TTM)Of every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
68.1%▲ +3.6% YoY
Operating Income (TTM)Profit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
$32M▲ +6.9% YoY
Free Cash Flow (TTM)Cash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
$10M▲ +6.9% YoY
StockOtter · stockotter.space

About KARDIGAN INC

Kardigan, Inc. is a clinical-stage precision therapeutics company, which engages in developing medicines that target the root cause of specific cardiovascular diseases where no approved treatments exist. It combines clinical-stage drug programs with artificial intelligence, real-world patient data, and analytics through its “Cardiac Intelligence” platform to accelerate research and improve treatment outcomes. The company was founded by Tassos E. Gianakakos, Jay Edelberg, Bob McDowell, Leslie Leinwand, and Elizabeth McNally in August 2023 and is headquartered in Princeton, NJ.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)
💎Quality★★★★★
🚀Growth★★★★★
⚖️Valuation★★★★★
⚡Momentum★★★★★
💧Dilution★★★★★
Overall Score
Fair
72/100

Analyst Price Target

ⓘ
Average Target
$18.39
▲ +25.3% Upside
High Target$20.40
Low Target$14.37
Based on 26 analysts

Latest News & Updates

🚀
MarketWatch·2h ago

KARDIGAN INC tops quarterly estimates as demand accelerates

Revenue grew double digits with management guiding above consensus; margins continued to expand.

🛰️
Reuters·5h ago

Analysts lift KARD price targets on improving margins

Several firms raised targets, citing stronger free cash flow and a healthier backlog.

🌌
Reuters·1d ago

KARDIGAN INC announces new agreement to expand its footprint

The move broadens the company’s reach and could add incremental revenue over the next year.